Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy Patients: A Cross-Sectional Study

Overview

Journal Turk J Gastroenterol

Publisher Aves

Specialty Gastroenterology

Date 2024 Dec 5

PMID 39632671

Authors

Semih Sezer

Selim Demirci

Murat Kara

Affiliations

Soon will be listed here.

Abstract

Background/aims: Cholecystectomy, while generally safe with low perioperative morbidity and mortality, has been linked to an increase in metabolic disorders. Metabolic dysfunction-associated fatty liver disease (MAFLD) is a globally prevalent condition that leads to both hepatic and systemic complications. This study aimed to investigate the association between cholecystectomy and MAFLD.

Materials And Methods: This cross-sectional study was designed to evaluate the relationship between cholecystectomy and MAFLD. Metabolic dysfunction-associated fatty liver disease was defined by the presence of hepatic steatosis in combination with any of the following conditions: diabetes mellitus (fasting plasma glucose ≥126 mg/dL), overweight (body mass index (BMI) ≥25 kg/m2), or metabolic dysregulation.

Results: A total of 163 participants with BMI ≥25 kg/m2, including consecutive cholecystectomized (N = 83) and non-cholecystectomized (N = 80) subjects, were included. The prevalence of MAFLD was found in 64 out of 83 (77.1%) cholecystectomized patients and in 30 out of 80 (37.5%) non-cholecystectomized subjects (P < .001). When age, gender, BMI, exercise habits, hypertension, diabetes mellitus, and cholecystectomy status were included in regression analyses, we found that only BMI [odds ratio (OR) = 1.155 (95% CI: 1.040-1.283)] and cholecystectomy [OR = 4.540 (95% CI: 2.200-9.370)] were independently associated with MAFLD (both P < .01). ROC analysis identified 10 years as the cut-off, with MAFLD risk being 2.7-7.3 times higher in patients with cholecystectomy for ≤10 and >10 years.

Conclusion: In our study, MAFLD was found to be 4.5 times more likely in cholecystectomized patients compared to those without cholecystectomy, with a significant increase in frequency observed after 10 years. These results suggest that cholecystectomized patients should be monitored for MAFLD.

References

Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View

Ayada I, van Kleef L, Alferink L, Li P, de Knegt R, Pan Q . Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. Liver Int. 2021; 42(2):277-287. DOI: 10.1111/liv.15139. View

Luo D, Chen X, Dai Y, Kuang F, Kang M, Li B . Cholecystectomy and risk of liver disease: a systematic review and meta-analysis of 27 million individuals. Int J Surg. 2023; 109(5):1420-1429. PMC: 10389609. DOI: 10.1097/JS9.0000000000000332. View

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Kullak-Ublick G, Paumgartner G, Berr F . Long-term effects of cholecystectomy on bile acid metabolism. Hepatology. 1995; 21(1):41-5. DOI: 10.1002/hep.1840210109. View

Sonne D, Hare K, Martens P, Rehfeld J, Holst J, Vilsboll T . Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. Am J Physiol Gastrointest Liver Physiol. 2013; 304(4):G413-9. DOI: 10.1152/ajpgi.00435.2012. View

Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne C, Targher G . Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020; 111S:154170. DOI: 10.1016/j.metabol.2020.154170. View

Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M . A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039. View

Fu L, John L, Adams S, Yu X, Tomlinson E, Renz M . Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004; 145(6):2594-603. DOI: 10.1210/en.2003-1671. View

10.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A . The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33. PMC: 1636651. DOI: 10.1186/1471-230X-6-33. View

11.

Shaffer E . Gallstone disease: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006; 20(6):981-96. DOI: 10.1016/j.bpg.2006.05.004. View

12.

Yilmaz Y, Yilmaz N, Ates F, Karakaya F, Gokcan H, Kaya E . The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study. Hepatol Forum. 2022; 2(2):37-42. PMC: 9138918. DOI: 10.14744/hf.2021.2020.0033. View

13.

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

14.

Amigo L, Husche C, Zanlungo S, Lutjohann D, Arrese M, Miquel J . Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int. 2010; 31(1):52-64. DOI: 10.1111/j.1478-3231.2010.02361.x. View

15.

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

16.

Watanabe M, Houten S, Wang L, Moschetta A, Mangelsdorf D, Heyman R . Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004; 113(10):1408-18. PMC: 406532. DOI: 10.1172/JCI21025. View

17.

Ruhl C, Everhart J . Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol. 2013; 108(6):952-8. DOI: 10.1038/ajg.2013.70. View

18.

Kim S, Lee J, Kim J, Kim K, Han J, Lee K . Appropriateness of a donor liver with respect to macrosteatosis: application of artificial neural networks to US images--initial experience. Radiology. 2005; 234(3):793-803. DOI: 10.1148/radiol.2343040142. View

19.

Cortes V, Barrera F, Nervi F . Pathophysiological connections between gallstone disease, insulin resistance, and obesity. Obes Rev. 2019; 21(4):e12983. DOI: 10.1111/obr.12983. View

20.

Pols T, Nomura M, Harach T, Lo Sasso G, Oosterveer M, Thomas C . TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011; 14(6):747-57. PMC: 3627293. DOI: 10.1016/j.cmet.2011.11.006. View